MeiraGTx: Hologen Partnership Makes Parkinson's Gene Therapy Vital
MeiraGTx Holdings plc (NASDAQ: MGTX ) is a genetic medicines biotech with a late-stage pipeline and capabilities for end-to-end GMP manufacturing. Its main drug candidates are AAV-AIPL1 for congenital blindness, which is working toward exceptional-circumstances filings and has a plannedMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens ...